Stockwatch: When pharma says return to sender
This article was originally published in Scrip
A steady stream of loss-making biotechnology companies reported their financial results for the last quarter of 2010 this week. The reporting of a little more, or a little less cash spent when the company has no product sales, in the cases of Cadence, Micromet Chelsea and Anadys, or on annual sales of $12m for Allos Therapeutics and $48m for Dendreon, is not likely to be a stock price moving event.
You may also be interested in...
Can the development of coronavirus vaccines and therapeutics reverse the demonization of the pharmaceutical sector brought about by drug price increases?
A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.
A complete response letter from the FDA knocked Intercept’s stock price for six, but perhaps the FDA is sending wider messages about NASH.